BridgeBio Pharma, Inc. (BBIO) - What Are Researchers Thinking About This Stock?

Key Points

• Analysts are broadly bullish: BridgeBio has a “Moderate Buy” consensus, with 19 buy, two hold, and one sell rating among 22 analysts. The average one-year price target is $104.26.
• Latest quarterly results beat expectations: BridgeBio reported a loss of $0.42 per share versus the expected $0.54 loss, while revenue of $353.17 million exceeded forecasts and rose 192.6% year over year.
• Company insiders sold 56,980 shares worth about $4.56 million over the past three months; institutional investors hold 99.85% of the stock.

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) has received an average rating of "Moderate Buy" from the twenty-two ratings firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nineteen have issued a buy rating on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $104.26.

A number of research analysts have weighed in on BBIO shares. Weiss Ratings lowered BridgeBio Pharma from a "sell (d)" rating to a "sell (d-)" rating in a report on Friday, September 25th. JPMorgan Chase & Co. upped their price target on BridgeBio Pharma from $100.00 to $111.00 and gave the company an "overweight" rating in a research report on Wednesday, August 12th. Bank of America increased their price target on shares of BridgeBio Pharma from $101.00 to $104.00 and gave the stock a "buy" rating in a report on Tuesday, August 11th. HC Wainwright restated a "buy" rating on shares of BridgeBio Pharma in a research report on Tuesday, October 6th. Finally, Truist Financial boosted their price objective on shares of BridgeBio Pharma from $102.00 to $107.00 and gave the company a "buy" rating in a research note on Wednesday, August 12th.

Insider Buying and Selling at BridgeBio Pharma

In other news, CEO Neil Kumar sold 34,980 shares of the company's stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $82.53, for a total value of $2,886,899.40. Following the transaction, the chief executive officer owned 243,327 shares of the company's stock, valued at approximately $20,081,777.31. This represents a 12.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Maricel Apuli sold 2,000 shares of the stock in a transaction on Friday, October 30th. The stock was sold at an average price of $72.85, for a total value of $145,700.00. Following the completion of the sale, the chief accounting officer owned 120,687 shares in the company, valued at $8,792,047.95. This trade represents a 1.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 56,980 shares of company stock valued at $4,563,699. Insiders own 14.23% of the company's stock.

Institutional Trading of BridgeBio Pharma

A number of large investors have recently modified their holdings of BBIO. Hsbc Holdings PLC grew its position in BridgeBio Pharma by 139.4% during the first quarter. Hsbc Holdings PLC now owns 32,708 shares of the company's stock valued at $2,431,000 after acquiring an additional 19,043 shares during the last quarter. Assetmark Inc. lifted its holdings in shares of BridgeBio Pharma by 423.7% in the 1st quarter. Assetmark Inc. now owns 20,790 shares of the company's stock worth $1,544,000 after acquiring an additional 16,820 shares during the last quarter. EFG International AG bought a new stake in shares of BridgeBio Pharma in the 2nd quarter worth approximately $6,117,000. Corient Private Wealth LP bought a new stake in shares of BridgeBio Pharma in the 2nd quarter worth approximately $1,783,000. Finally, Squarepoint Ops LLC boosted its stake in shares of BridgeBio Pharma by 114.2% in the 2nd quarter. Squarepoint Ops LLC now owns 1,191,732 shares of the company's stock valued at $88,760,000 after purchasing an additional 635,408 shares in the last quarter. Institutional investors own 99.85% of the company's stock.

BridgeBio Pharma Price Performance

Shares of BBIO stock opened at $79.54 on Thursday. The company's fifty day simple moving average is $69.89 and its two-hundred day simple moving average is $72.79. BridgeBio Pharma has a 1 year low of $62.50 and a 1 year high of $93.42. The stock has a market capitalization of $15.49 billion, a price-to-earnings ratio of -26.16 and a beta of 0.97.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last posted its earnings results on Thursday, October 29th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.12. The company had revenue of $353.17 million for the quarter, compared to analysts' expectations of $293.47 million. The company's revenue was up 192.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.95) EPS. Equities research analysts anticipate that BridgeBio Pharma will post -2.55 EPS for the current year.

BridgeBio Pharma Company Profile

BridgeBio Pharma is a biopharmaceutical company that discovers, develops and commercializes medicines for genetic diseases and cancers. Founded in 2015, the company advances programs through a network of research and development subsidiaries focused on specific conditions and therapeutic areas. Its products include Attruby (acoramidis), an FDA-approved treatment for adults with transthyretin amyloid cardiomyopathy. BridgeBio also develops a pipeline of investigational therapies aimed at diseases with well-understood genetic causes, including rare and inherited conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.